![A 44-year-old woman presented with a palpable right supraclavicular mass. Excisional biopsy revealed involvement by classical Hodgkin lymphoma (cHL), nodular sclerosis subtype. Hematoxylin and eosin–stained sections showed a lymph node partially effaced by vaguely nodular infiltrates composed of large, frankly malignant lymphoid cells. The abnormal large cells included binucleated Reed-Sternberg cells (panel A, red arrows; original magnification ×40). By immunohistochemistry stain, the cells expressed CD30 (panel C; original magnification ×40) and PAX5 without CD15 or BOB1. Additionally, a nodular proliferation of Langerhans cells with grooved nuclei, fine chromatin, and abundant eosinophilic cytoplasm was noted (panel A, blue arrows; original magnification ×40). By immunohistochemistry stain, the cells were positive for CD1a (panel B; original magnification ×40) and S100. The sample tested positive for the BRAF p.V600E mutation (NM_004333.4:c.1799T>A) by next-generation sequencing and immunohistochemistry stain (panel D, red arrows; original magnification ×40). A diagnosis of nodular sclerosis cHL with foci of Langerhans cell histiocytosis (LCH) was rendered. The patient was treated with 4 cycles of ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) chemotherapy followed by 30.6-Gy radiation. A year later, she remains in complete remission. / Previous case studies suggest a higher prevalence of hematologic and solid malignancies among LCH patients both preceding, concurrent with, and following a diagnosis of LCH. Interestingly, our case demonstrates a concurrent cHL and LCH diagnosis in which a BRAF mutation was isolated in lesional tissue.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/133/19/10.1182_blood-2019-01-891937/3/m_blood891937f1.png?Expires=1764993089&Signature=tKCKU9sGd~aANgVgpaP3UcMlio5m0tFohQSd6q-62K4gcmBMrLvFl72sZNjK2hjt4E6PtYNde0rIUghqdu1JLUt5V7zvBl5pVAcEvb8jEpwqbvEVey2ee9T9mBb5dx7s4ACbeCGBsNjVTvw2NBeGP0eRiGQUBkuMHR~5vl4zhLBmXYQdL2K2xczqG29LZvTDp8k~kUyXNcEIs3mTAa5mHLPATU~55Qz93rYe97FrkxgGCl3sj3zqJ6H98z~vYfWUZkWUr1IxZB7j7DOWvMMXofWTopNAXBE~Sz0B1fV8iH0auwzpzMnBDxnWjU5VPMnLxIgU51VTJff5VQUr2YZq2A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
A 44-year-old woman presented with a palpable right supraclavicular mass. Excisional biopsy revealed involvement by classical Hodgkin lymphoma (cHL), nodular sclerosis subtype. Hematoxylin and eosin–stained sections showed a lymph node partially effaced by vaguely nodular infiltrates composed of large, frankly malignant lymphoid cells. The abnormal large cells included binucleated Reed-Sternberg cells (panel A, red arrows; original magnification ×40). By immunohistochemistry stain, the cells expressed CD30 (panel C; original magnification ×40) and PAX5 without CD15 or BOB1. Additionally, a nodular proliferation of Langerhans cells with grooved nuclei, fine chromatin, and abundant eosinophilic cytoplasm was noted (panel A, blue arrows; original magnification ×40). By immunohistochemistry stain, the cells were positive for CD1a (panel B; original magnification ×40) and S100. The sample tested positive for the BRAF p.V600E mutation (NM_004333.4:c.1799T>A) by next-generation sequencing and immunohistochemistry stain (panel D, red arrows; original magnification ×40). A diagnosis of nodular sclerosis cHL with foci of Langerhans cell histiocytosis (LCH) was rendered. The patient was treated with 4 cycles of ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) chemotherapy followed by 30.6-Gy radiation. A year later, she remains in complete remission.
Previous case studies suggest a higher prevalence of hematologic and solid malignancies among LCH patients both preceding, concurrent with, and following a diagnosis of LCH. Interestingly, our case demonstrates a concurrent cHL and LCH diagnosis in which a BRAF mutation was isolated in lesional tissue.
A 44-year-old woman presented with a palpable right supraclavicular mass. Excisional biopsy revealed involvement by classical Hodgkin lymphoma (cHL), nodular sclerosis subtype. Hematoxylin and eosin–stained sections showed a lymph node partially effaced by vaguely nodular infiltrates composed of large, frankly malignant lymphoid cells. The abnormal large cells included binucleated Reed-Sternberg cells (panel A, red arrows; original magnification ×40). By immunohistochemistry stain, the cells expressed CD30 (panel C; original magnification ×40) and PAX5 without CD15 or BOB1. Additionally, a nodular proliferation of Langerhans cells with grooved nuclei, fine chromatin, and abundant eosinophilic cytoplasm was noted (panel A, blue arrows; original magnification ×40). By immunohistochemistry stain, the cells were positive for CD1a (panel B; original magnification ×40) and S100. The sample tested positive for the BRAF p.V600E mutation (NM_004333.4:c.1799T>A) by next-generation sequencing and immunohistochemistry stain (panel D, red arrows; original magnification ×40). A diagnosis of nodular sclerosis cHL with foci of Langerhans cell histiocytosis (LCH) was rendered. The patient was treated with 4 cycles of ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) chemotherapy followed by 30.6-Gy radiation. A year later, she remains in complete remission.
Previous case studies suggest a higher prevalence of hematologic and solid malignancies among LCH patients both preceding, concurrent with, and following a diagnosis of LCH. Interestingly, our case demonstrates a concurrent cHL and LCH diagnosis in which a BRAF mutation was isolated in lesional tissue.
For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal